Immunohistochemistry (IHC) Troubleshooting Guide

Practical solutions for weak or absent staining, high background, overstaining and nonspecific IHC staining, with control-based checks to help distinguish technical artifacts from true expression patterns.

How to Troubleshoot IHC Effectively

Consistent IHC results require more than following protocol steps. Compare the staining pattern with expected target localization and verify that positive, negative and detection-system controls behave as expected before adjusting experimental conditions.

Sample preparation, antigen retrieval, blocking, primary antibody incubation and detection each influence signal and background. When troubleshooting, check specimen and control performance first, then change one validated parameter at a time.

Use the troubleshooting tables below for common staining problems. For expanded guidance, access the Boster IHC Troubleshooting Handbook or the IHC Optimization resources.

For unexpected results, jump to false-positive/false-negative checks or control-based troubleshooting.

Troubleshooting Guides

troubleshooting_box_image

Download troubleshooting handbooks for IHC, Western blot and ELISA for FREE.

Troubleshooting guides

Save Time & Money Now!

Did you know that Boster can accelerate your research projects by assisting you in antibody validation?

Common IHC Troubleshooting Issues and Solutions

The following guide serves as a checklist for identifying and resolving common protocol issues encountered during IHC staining. Addressing these challenges effectively can save time, and resources, and ensure high-quality staining results.

In July 2020, our team interviewed industry experts and composed an in-depth interview for topics of optimizing and troubleshooting IHC. It answers many interesting questions and you can see more details here: Boster Interview Series: Expert Tips on IHC

No Or Weak Staining

Weak staining of CD3 epsilon in human tonsil tissue

Weak staining of CD3 epsilon in human tonsil tissue

Improved staining of CD3 epsilon in human tonsil tissue

Improved staining of CD3 epsilon in human tonsil tissue

Good IHC results rely on strong, specific staining of the target antigen. Weak or lack of staining often requires repeating the experiment, which can be costly in terms of time and resources. Use the table below to identify and correct the source of weak staining.

S.No. Possible Cause Solution
1 Signal loss or variability in stored unstained tissue sections
  • Use freshly cut sections when antigen stability is uncertain.
  • Store blocks and unstained slides under validated conditions appropriate to tissue, target and duration.
  • Follow the validated drying/baking procedure for slide adhesion; avoid unnecessary prolonged heat exposure.
2 The antibody has not been validated for the sample preparation and IHC application used
  • Confirm IHC-P or IHC-F validation in the product datasheet and the relevant sample species.
  • Use appropriate positive and negative tissue controls with the expected subcellular localization.
  • Western blot evidence can support antibody characterization, but cannot replace application-specific IHC validation.
3 Fixation procedures (using formalin and paraformaldehyde fixatives) have masked the epitope that the antibody recognizes
  • Review tissue fixation conditions and compare with a known positive control processed in a comparable way.
  • Optimize antigen retrieval method, buffer, pH and exposure for the specific antigen and tissue; avoid indiscriminately increasing retrieval.
  • Adjust fixation only within a validated sample-preparation protocol.
4 The primary and/or secondary antibody has lost its activity due to improper storage, dilution, or excessive freezing and thawing
  • Run positive controls to ensure that the primary and/or secondary antibody is working properly.
  • Store the antibodies according to manufacturer instructions.
  • Avoid contamination and light on antibodies.
5 Insufficient deparaffinization
  • Increase the deparaffinization time
  • Use fresh dimethylbenzene
6 Limited antibody access to an intracellular or nuclear epitope
  • Confirm that the antigen is expected in the indicated compartment.
  • For cell-based ICC/IF, use fixation and permeabilization conditions appropriate for the antigen.
  • For tissue sections, reassess fixation and epitope retrieval; detergent treatment is not automatically appropriate for every IHC sample.
7 Contaminated or improperly prepared buffer may compromise reproducibility
  • Prepare fresh, clean wash buffer and check pH and reagent compatibility.
  • Do not add sodium azide to working solutions used with HRP-based detection: azide can inhibit HRP activity.
  • Follow product-specific preservation instructions for antibody stock solutions; do not assume preservative-containing stocks are compatible with all detection systems.
8 The primary antibody and the secondary antibody are not compatible
  • Use a secondary antibody that was raised against the species in which the primary was raised (e.g. if the primary antibody was raised in mouse, an anti-mouse secondary antibody should be used)
  • Check that the isotypes of the primary and secondary are compatible
9 The protein is not present in the tissue of interest or has not sufficiently expressed
  • Stain a separate tissue or cell sample known to express the target to confirm assay performance.
  • Review expression data and any internal positive control in the test sample; a true negative result is possible.
  • Consider signal amplification only when specificity and background remain acceptable.
10 Insufficient antibody to detect protein of interest
  • Use a higher antibody concentration
  • Incubate for a longer time (e.g. overnight) at 4°C
11 Tissues dried out
  • Cover the tissues in liquid at all times during the experiment.
12 Chromogen or enzyme detection reagents are inactive, expired or incompatible
  • Confirm that the enzyme label matches the chromogen (for example, HRP with DAB, or AP with an AP-compatible substrate).
  • Use freshly prepared detection reagents and the substrate buffer recommended for the kit.
  • Check processing times and run a known positive control before modifying development conditions.
13 Buffer incompatible with enzyme
  • Use enzyme-compatible wash and substrate buffers; phosphate-containing buffers can interfere with some AP detection systems.
  • Avoid sodium azide in HRP-containing detection or development solutions.
14 Inadequate antigen retrieval
  • Compare retrieval buffer and pH, as well as time and temperature, against the target-specific protocol.
  • Review fixation and known positive control performance before changing retrieval.
  • Excessive retrieval may damage morphology or reduce signal; do not automatically lengthen retrieval.

For a more detailed exploration of weak staining issues, check out our advanced guide on troubleshooting IHC experiments.

High Background Staining

High background can obscure tissue features and reduce the signal-to-noise ratio. It may result from primary or secondary antibody binding, insufficient blocking, endogenous enzyme/biotin activity, tissue autofluorescence in IF, or sample preparation artifacts.

High background staining of rat brain tissue using anti-VCP antibody

High background staining of rat brain tissue using anti-VCP antibody

Improved staining of VCP in rat brain tissue

Improved staining of VCP in rat brain tissue

Solutions to High Background Staining

S.No. Possible Cause Solution
1 The blocking serum is incorrect
  • Make sure to block according to the provided protocol.
2 Blocking is insufficient
(Do not over-block the tissue because antigenic sites may be masked)
  • Titrate the blocking agent and duration using a matched negative control.
  • Select serum, BSA or another blocker appropriate to the primary/secondary antibodies and tissue; blocking conditions vary by assay.
3 The primary antibody concentration is too high
  • Perform an IHC-specific titration of primary antibody concentration and incubation time.
  • Reduce primary antibody concentration or incubation strength if negative tissue shows unwanted staining.
4 Non-specific binding by secondary antibody
  • Run a no-primary control to identify signal from the secondary antibody or detection system; it does not establish primary-antibody specificity.
  • If that control stains, check secondary-antibody cross-reactivity, species cross-adsorption, and blocking conditions.
  • Compare an appropriate negative tissue or genetically depleted control when evaluating primary-antibody specificity.
5 Endogenous peroxidase or alkaline phosphatase activity produces background in enzyme-based detection
  • For HRP detection, use an appropriate hydrogen-peroxide quenching step according to the validated tissue protocol.
  • For susceptible endogenous AP activity, levamisole may be useful; it does not inhibit every AP isoenzyme.
  • Select quenching conditions according to the chromogen, enzyme conjugate and tissue.

To reduce background staining further, see our in-depth high-background DAB troubleshooting guide.

Overstaining

Overstaining of mouse liver tissue stained with anti-SC10A1 antibody

Overstaining of mouse liver tissue stained with anti-SC10A1 antibody.

Improved staining of VSC10A1 in mouse liver tissue

Improved staining of VSC10A1 in mouse liver tissue

Overstaining occurs when an increase in signal reduces contrast, making it difficult to analyze tissue structures accurately. Below are some tips to avoid overstaining.

Troubleshooting Overstaining

S.No. Possible Cause Solution
1 Primary antibody too concentrated
  • Titrate the primary antibody using a validated IHC positive/negative tissue pair.
  • Use the lowest concentration that preserves the expected signal with acceptable background.
2 Excessive primary antibody binding
  • Reduce the length of the incubation step.
  • Incubate in a cold room at 4°C.
3 Detection substrate incubation time too long
  • Allow less time for signal development after adding the detection substrate.
4 Insufficient washing
  • Increase the number and time of washes.

Nonspecific Staining

Nonspecific staining of human tonsil tissue stained with anti-CD3 Epsilon antibody

Nonspecific staining of human tonsil tissue stained with anti-CD3 Epsilon antibody

Improved staining of CD3 Epsilon in human tonsil tissue

Improved staining of CD3 Epsilon in human tonsil tissue

Nonspecific staining may arise from off-target antibody binding, inadequate blocking, endogenous tissue activity, or detection-system background. Compare the pattern with positive/negative tissue and no-primary controls before attributing the signal to the target.

S.No. Possible Cause Solution
1 Inadequate deparaffinization of the tissue section
  • Increase deparaffinization time.
  • Use fresh dimethyl benzene.
2 Unquenched endogenous peroxidase or endogenous biotin in avidin/streptavidin-based detection
  • For HRP systems, apply appropriate endogenous-peroxidase blocking.
  • If using an avidin/biotin method, consider a validated avidin–biotin blocking protocol or a biotin-free polymer detection system.
  • Interpret background using no-primary and negative tissue controls.
3 Insufficient blocking
  • Increase blocking time.
4 Section dried out
  • Avoid allowing your tissue section to dry out.
5 Insufficient washing
  • Increase the washing time and number of washes.
6 Antibody degradation, contamination, cross-reactivity or off-target binding
  • Check antibody handling and reagent integrity; replace contaminated or degraded stock.
  • Use appropriate negative tissues and, where feasible, an alternative clone or genetic-depletion control.
  • Do not assume an affinity purification step alone establishes target specificity.
7 Excessive primary antibody concentration
  • Reduce antibody concentration.

Unlock new dimensions of biological insight with multiplex IHC! By examining multiple biomarkers simultaneously, our cutting-edge platform allows you to unravel intricate cellular interactions and gain valuable insights for your research.

False-Positive vs. False-Negative IHC Results

A stained section can be misleading in either direction. An unexpected signal may reflect off-target binding or detection-system background, while a missing signal may reflect epitope loss, inadequate retrieval or a true absence of the target. Review control results and the expected tissue localization before interpreting the pattern.

PatternPossible explanationFirst check
Unexpected positive stainingAntibody cross-reactivity, nonspecific reagent binding, endogenous enzyme/biotin activity or staining artifactExamine negative tissue and no-primary controls separately; review localization and detection chemistry
Expected positive tissue stains weakly or not at allReagent failure, unsuitable retrieval, fixation damage or an incompatible antibody/detection systemConfirm the positive control and protocol details before increasing antibody concentration
Test tissue is negative, but external positive control passesTrue low/absent target expression, specimen-specific preanalytic problems or heterogeneous expressionCheck the internal positive control, specimen processing history and expected expression
Signal appears in an unexpected cell compartmentTechnical artifact, antibody cross-reactivity or a biologically altered localization patternCompare with validated localization and an alternative control or method when available

A positive or negative IHC result is not defined solely by staining intensity. Interpretation depends on appropriate controls, expected target distribution and, where relevant, a validated scoring method.

Troubleshoot IHC Using Your Controls

Controls help distinguish a specimen problem from an assay problem. Choose positive and negative tissues appropriate to the target and, whenever possible, include an internal positive cell population in the tested specimen.

Control observationWhat it suggestsNext action
Known positive tissue and test tissue are both blankThe staining run or detection conditions may have failedCheck retrieval, primary/secondary compatibility, substrate activity and instrument/protocol steps
Positive control stains, but test tissue is blankTarget expression may be absent, or specimen-specific processing may have reduced detectabilityCheck internal positive cells, tissue handling and another section/block where appropriate
Known negative tissue stains unexpectedlyPotential off-target antibody binding or assay backgroundReview antibody validation and concentration; compare negative-reagent and detection-system controls
No-primary control shows stainingSignal may arise from the secondary/detection chemistry or specimen backgroundInspect blocking, endogenous enzyme/biotin activity and secondary-antibody cross-reactivity
Internal positive cells fail within the test specimenNegative staining in the cells of interest may not be interpretableReassess specimen fixation, processing and antigen preservation before interpreting the result

Control limitation: A no-primary control is useful for detecting background from secondary reagents and the detection system, but it cannot by itself demonstrate that the primary antibody binds only the intended antigen. Use appropriate negative tissue or genetically depleted material, when feasible, together with other validation evidence.

For further details, see 6 IHC Controls You Should Know and IHC Optimization.

Specimen Preparation: The Foundation of Successful IHC

Proper specimen preparation is critical to maintaining tissue morphology and preserving target epitopes, setting the foundation for any successful IHC protocol. Depending on whether analysis will be done by fluorescence or light microscopy, the preparation methods can vary.

Tissue Collection and Fixation

Tissue must be collected and preserved efficiently to prevent degradation and preserve cell and tissue structure. Two main methods are used:

  • Frozen Tissue: Rapidly freeze tissue using a protocol suitable for the target, prepare cryostat sections, and control freezing artifacts and fixation conditions.
  • FFPE (Formalin-Fixed, Paraffin-Embedded): Preserves tissue architecture for paraffin sectioning and archival analysis, but antigenicity can change with fixation and storage conditions.

Cryopreservation Best Practices

After dissection, fresh tissue should be rapidly frozen in chilled isopentane to prevent ice crystal formation. Once frozen, it is stored at -80°C until sectioning. Larger tissues may need to be cut into smaller blocks to ensure even freezing.

Antigen Retrieval for Improved Staining

For FFPE tissues, epitopes may become inaccessible due to fixation. Antigens can be unmasked through:

  • HIER (Heat-Induced Epitope Retrieval)
  • PIER (Protease-Induced Epitope Retrieval)

Both methods aid in restoring antigen accessibility for antibody binding.

Selecting the Right Antibodies for IHC

Choosing the right antibodies is a critical step in ensuring effective IHC results. The following factors should be carefully considered:

  • Specificity: Assess expected tissue and subcellular localization using positive and negative controls. KO/KD or an orthogonal method can strengthen evidence; a single Western blot band alone does not prove IHC specificity.
  • Application suitability: Confirm the antibody is validated for IHC-P or IHC-F and the tissue or species of interest. Fixation and retrieval can alter epitope accessibility; IHC does not universally preserve a protein's native conformation.
  • Clonality: Monoclonal and polyclonal antibodies may differ in sensitivity, epitope coverage and cross-reactivity. Performance must be evaluated for the specific antibody and sample.
  • Primary and secondary compatibility: Match the secondary antibody to the primary host and isotype, and choose a detection system compatible with the assay. Same-species tissue and primary-host workflows may require additional blocking or specialized methods.
  • Blocking and background: Optimize blocking for the tissue and detection system; verify reduced nonspecific background with appropriate negative controls. See IHC Optimization.

Careful consideration of these factors ensures that antibodies perform optimally, resulting in clear, specific staining and accurate data interpretation.

Unlock Deeper Insights with Multiplex IHC

Maximize your research potential with multiplex IHC, which enables the simultaneous visualization of multiple biomarkers. This advanced technique offers a comprehensive view of cellular interactions, unlocking new avenues for your research.

Learn more about our cutting-edge multiplex IHC solutions.

Related Pages for IHC Troubleshooting

IHC Principle

Learn the basic principle of immunohistochemistry (IHC), including how antibodies bind specifically to antigens in tissue sections for target detection.

Learn More

IHC Protocol

Review a step-by-step IHC protocol with a clear workflow and recommended reagents to support successful immunostaining for tissue sections and cell samples.

Learn More

IHC Optimization Tips

Explore key IHC optimization tips for antigen retrieval, fixation, and embedding to improve staining quality and experimental consistency.

Learn More

IHC Sample Preparation Guidelines

Learn IHC and ICC/IF sample preparation methods, including preserved tissue handling steps that support high-quality staining results.

Learn More

Multiplex IF Troubleshooting

Troubleshoot multiplex IF issues such as bleed-through, weak signal, and high background with practical controls and quick checks.

Learn More

Weak or No Staining in IHC

Weak or no staining in IHC usually points to one of four places: the sample, antigen retrieval, primary antibody conditions, or the detection layer.

Learn More

How to Troubleshoot High Background in DAB Staining

High background in DAB staining usually shows up as one of three patterns: a global brown/gray haze, edge-darkening, or granular brown speckling.

Learn More

Choosing Fluorophores for Multiplex IF

Learn how to choose fluorophores for multiplex IF based on marker abundance, brightness, and channel planning for cleaner panel design.

Learn More